TY - JOUR ID - 66113 TI - Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 AU - Makvandi, Manoochehr AU - Soleimani Jelodar, Rahim AU - Samabafzadeh, Alireza AU - Neisi, Niloofar AU - Sharifi, Zohreh AU - Gholampour, Azadeh AU - Masjedizadeh, Abdolrahim AU - Shayesteh, Aliakbar AD - Infectious and Tropical Disease Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. AD - Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran. AD - Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran. AD - Division of Gastroenterology, Department of Internal Medicine, Imamkhomini hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Y1 - 2018 PY - 2018 VL - 19 IS - 8 SP - 2125 EP - 2129 KW - Chronic Hepatitis B (CHB) KW - HBsAg KW - HBeAg KW - Alanine Aminotransferase (ALT) Real-Time PCR DO - 10.22034/APJCP.2018.19.8.2125 N2 - Objective: A long persistent of Chronic Hepatitis B (CHB) infection may develop liver cirrhosis or hepatocellularcarcinoma (HCC) and about one million people die due to HBV -related liver cancer and end-stage liver disease annuallyworldwide. The natural history of CHB phases comprises four phases: immune tolerant (HBeAg detectable and ALT(Alanine Transaminase) normal, HBeAg-positive immune active (HBeAg detectable, anti-HBe antibodies undetectableand ALT persistently elevated), HBeAg-negative immune active (HBeAg undetectable, anti-HBe antibodies presentand ALT persistently elevated), inactive carrier (HBeAg undetectable, anti-HBe antibodies present and ALT normal).The evaluation of chronic hepatitis B phases is a crucial to manage the burden of disease and limit the developmentof associated complications, such as cirrhosis and hepatocellular carcinoma (HCC). Thus this study conducted toevaluate the natural history of HBV infection in patients with chronic HBV infection in Ahvaz city, Iran. Methods: Inthis study, 71 non-treated CHB individuals were recruited including 44 (62%) males and 27(38%) females. The serawere tested for HBV markers, HBsAg, HBcIgG, HBeAg, and HBeAb. ALT assay and HBV viral load were carried outfor each CHB individual. Results: Based on the analysis of serological, ALT status and viral load, the results showed:immune tolerance 5(7%), eAg+ Immune Clearance 14(19.7%), eAg- Immune Clearance 29 (40.84%) and InactiveCarrier 23 (32.39%). The HBeAg seroconversion was observed in a male age 18 year. Conclusion: The results ofthe natural history of individuals with chronic hepatitis B phases CHB shows immune tolerance (7%), eAg+ ImmuneClearance (19.7%), eAg- Immune Clearance (40.84%) and Inactive Carrier (32.39%). To prevent the consequence ofCHB infection, an individual in immune tolerance phase should be tested periodically for ALT level, HBV markers,HBsAg, HBcIgG, HBeAg, HBeAb and HBV viral load. Then decision-making therapy can be applied for CHB patientsat early stage of immune clearance. UR - https://journal.waocp.org/article_66113.html L1 - https://journal.waocp.org/article_66113_2f7373b42b787bc5c259be7e499707a3.pdf ER -